Review
Open access
Sep 2026
Efficacy and safety of T-DXd versus Other HER2-targeted therapies in second-line and later settings for HER2-positive metastatic breast cancer: A Bayesian network meta-analysis
Background HER2-positive advanced breast cancer remains challenging after trastuzumab-based therapy because available regimens differ in survival, response, and toxicity. We compared therapies used in second-line and later settings. Methods This PRISMA-NMA-compliant review was registered with PROSPERO (CRD420251244047)...
Yu Xiao, Jing Fu, Juan Li et al.
· PLoS ONE · 0 citations